<tei>
    <teiHeader>
        <fileDesc xml:id="_Blauvelt 2021.pdf"/>
    </teiHeader>
    <text xml:lang="en">


		<figure type="table">

            <table>183 men [52.6%];<lb/> mean [SD] age, 36.6 [14.6] years) received upadacitinib, and 344<lb/> (194 men [56.4%]; mean [SD] age, 36.9 [14.1] years) received du-<lb/>pilumab. The number of patients who discontinued treatment<lb/> was low overall; 316 (90.8%) completed upadacitinib treat-<lb/>ment, and 319 (92.7%) completed dupilumab treatment<lb/> (Figure</table>
		</figure>


		<figure type="table">

            <table>924 Patients assessed for eligibility<lb/> via physical examination<lb/> 232 Excluded<lb/> 692 Patients randomized and treated<lb/> 344 Assigned to dupilumab<lb/> 344 Treated with active treatment<lb/> 70 Received rescue medication<lb/> before week 16<lb/> 348 Assigned to upadacitinib<lb/> 348 Treated with active treatment<lb/> 61 Received rescue medication<lb/> before week 16<lb/> 328 Completed study drug<lb/> through week 16<lb/> 15 Received rescue medication<lb/> after week 16<lb/> 336 Completed study drug<lb/> through week 16<lb/> 27 Received rescue medication<lb/> after week 16<lb/> 319 Completed study drug through<lb/> week 24<lb/> 316 Completed study drug through<lb/> week 24<lb/> 16 Discontinued treatment<lb/> 2 Adverse event<lb/> 7 Withdrew consent<lb/> 4 Lost to follow-up<lb/> 3 Other<lb/> 9 Discontinued treatment<lb/> 2 Adverse event<lb/> 3 Lack of efficacy<lb/> 1 Withdrew consent<lb/> 1 Lost to follow-up<lb/> 2 Other<lb/> 20 Discontinued treatment<lb/> 7 Adverse event<lb/> 6 Lack of efficacy<lb/> 3 Withdrew consent<lb/> 3 Lost to follow-up<lb/> 1 Other<lb/> 12 Discontinued treatment<lb/> 3 Adverse event<lb/> 5 Withdrew consent<lb/> 1 Lost to follow-up<lb/> 1 COVID-19 logistics<lb/> 2 Other<lb/> CONSORT diagram for patient enrollment, randomization, and discontinuation.<lb/> The primary reason for discontinuation is listed. EASI indicates Eczema Area and<lb/> Severity Index.<lb/> </table>
<lb/> 
            <note>Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis<lb/> Original Investigation Research<lb/> jamadermatology.com<lb/> (Reprinted) JAMA Dermatology September 2021 Volume 157, Number 9 </note>
 
            <table>NRS improvement ≥4 points from baseline) at week 16 was<lb/> higher for those who received upadacitinib compared with<lb/> those who received dupilumab (188 of 340 [55.3%] vs 120 of<lb/> 336 [35.7%]; P &lt; .001). Thus, the study met all ranked sec-<lb/>ondary efficacy end points, demonstrating that upadaci-<lb/>tinib achieved significantly greater improvements in both<lb/> investigator-and patient-reported outcomes compared with<lb/> dupilumab.<lb/> Numerically greater proportions of upadacitinib-treated vs<lb/> dupilumab-treated patients achieved EASI75 as early as week 1<lb/> (55 of 348 [15.9%] vs 19 of 344 [5.5%]) and at week 4 (243 of 348<lb/> [69.9%] vs 123 of 344 [35.9%]) (Figure 2A). Similar differences<lb/> were observed for achievement of EASI90 at week 2 (64 of 348<lb/> [18.5%] vs 20 of 344 [5.8%]) and week 8 (206 of 48 [59.2%] vs 86<lb/> of 344 [25.1%]) (Figure</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>1</label>

            <head>. </head>
 
            <figDesc>Baseline Demographic and Disease Characteristics of Patients a<lb/> </figDesc>
<lb/> 
            <table>Characteristic<lb/> Patients, No. (%)<lb/> Dupilumab, 300 mg<lb/> (n = 344)<lb/> Upadacitinib, 30 mg<lb/> (n = 348)<lb/> Sex<lb/> Male<lb/> 194 (56.4)<lb/> 183 (52.6)<lb/> Female<lb/> 150 (43.6)<lb/> 165 (47.4)<lb/> Age, mean (SD) [range], y<lb/> 36.9 (14.09)<lb/> [18-76]<lb/> 36.6 (14.61) [18-76]<lb/> Age group, y<lb/> &lt;40<lb/> 226 (65.7)<lb/> 228 (65.5)<lb/> ≥40 to &lt;65<lb/> 101 (29.4)<lb/> 102 (29.3)<lb/> ≥65<lb/> 17 (4.9)<lb/> 18 (5.2)<lb/> Disease duration since<lb/> diagnosis, mean (SD), y<lb/> 25.0 (14.8)<lb/> 23.5 (14.7)<lb/> Weight, mean (SD), kg<lb/> 75.6 (18.4)<lb/> 78.8 (22.3)<lb/> BMI, mean (SD)<lb/> 25.99 (5.72)<lb/> 26.99 (6.53) b<lb/> BSA, mean (SD), %<lb/> 44.4 (22.8)<lb/> 48.2 (24.0)<lb/> vIGA-AD score<lb/> 3 (Moderate)<lb/> 171 (49.7)<lb/> 174 (50.0)<lb/> 4 (Severe)<lb/> 173 (50.3)<lb/> 174 (50.0)<lb/> EASI, mean (SD)<lb/> 28.8 (11.5)<lb/> 30.8 (12.5)<lb/> Worst Pruritus NRS [weekly<lb/> average], mean (SD)<lb/> 7.5 (1.7)<lb/> 7.4 (1.6)<lb/> </table>
<lb/> 
            <note>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided<lb/> by height in meters squared); BSA, body surface area; EASI, Eczema Area and<lb/> Severity Index; NRS, Numerical Rating Scale; vIGA-AD, validated Investigator&apos;s<lb/> Global Assessment.<lb/> <note>a Baseline demographic and disease characteristics assessed upon entry to<lb/> Heads Up (study M16-046).<lb/> <note>b Data shown for 347 patients.</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>2</label>

            <head>. </head>
 
            <figDesc>Primary and Ranked Secondary End Points<lb/> </figDesc>
<lb/> 
            <table>End point<lb/> Time point<lb/> Dupilumab, 300 mg (n = 344)<lb/> Upadacitinib, 30 mg (n = 348)<lb/> Difference<lb/> P value<lb/> Primary end point<lb/> Achievement of<lb/> EASI75 a<lb/> Week 16<lb/> 210 (61.1) [55.9 to 66.2]<lb/> 247 (71.0) [66.2 to 75.8]<lb/> 10<lb/> .006<lb/> Secondary end points<lb/> in order of ranking<lb/> % Change from<lb/> baseline in worst<lb/> pruritus NRS b<lb/> Week 16<lb/> −49.0 (2.0) [-52.9 to −45.2]<lb/> −66.9 (1.9) [-70.6 to −63.2]<lb/> −17.84<lb/> &lt;.001<lb/> No.<lb/> 251<lb/> 258<lb/> Achievement of<lb/> EASI100 a<lb/> Week 16<lb/> 26 (7.6) [4.8 to10.4]<lb/> 97 (27.9) [23.2 to 32.6]<lb/> 20.3<lb/> &lt;.001<lb/> Achievement of<lb/> EASI90 a<lb/> Week 16<lb/> 133 (38.7) [33.6 to 43.9]<lb/> 211 (60.6) [55.4 to 65.7]<lb/> 21.8<lb/> &lt;.001<lb/> % Change from<lb/> baseline in Worst<lb/> Pruritus NRS b<lb/> Week 4<lb/> −31.7 (2.2) [-36.1 to −27.3]<lb/> −59.5 (2.2) [-63.8 to −55.2]<lb/> −27.8<lb/> &lt;.001<lb/> No.<lb/> 310<lb/> 333<lb/> Achievement of<lb/> EASI75 a<lb/> Week 2<lb/> 60 (17.5) [13.5 to 21.5]<lb/> 152 (43.7) [38.4 to 48.8]<lb/> 26.0<lb/> &lt;.001<lb/> % Change from<lb/> baseline in Worst<lb/> Pruritus NRS b<lb/> Week 1<lb/> −8.8 (1.8) [-12.3 to −5.3]<lb/> −31.4 (1.7) [-34.9 to −28.0]<lb/> −22.7<lb/> &lt;.001<lb/> No.<lb/> 327<lb/> 337<lb/> Worst Pruritus NRS<lb/> improvement ≥4<lb/> points a,c<lb/> Week 16<lb/> 120 (35.7) [30.7 to 41.0]<lb/> 188 (55.3) [49.9 to 60.5]<lb/> 19.3<lb/> &lt;.001<lb/> No.<lb/> NA<lb/> 336<lb/> 340<lb/> NA<lb/> NA<lb/> </table>
<lb/> 
            <note>Abbreviations: EASI75, 75% improvement in the Eczema Area and Severity<lb/> Index; NA, not applicable; NRS, Numerical Rating Scale.<lb/> <note>a No. (%) [95% CI].<lb/> <note>b Least-squares mean (SD) [95% CI].<lb/> <note>c Analyzed for patients with Worst Pruritus NRS of 4 points or higher at<lb/> baseline.<lb/> Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis<lb/> Original Investigation Research<lb/> jamadermatology.com<lb/> (Reprinted) JAMA Dermatology September 2021 Volume 157, Number 9</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>3</label>

            <head>. </head>
 
            <figDesc>TEAEs Through Week 16 for All Patients Receiving<lb/> 1 Dose or More of Study Drug<lb/> </figDesc>
<lb/> 
            <table>TEAE<lb/> Patients, No. (%)<lb/> Dupilumab,<lb/> 300 mg (n = 344)<lb/> Upadacitinib,<lb/> 30 mg (n = 348)<lb/> AE<lb/> 216 (62.8)<lb/> 249 (71.6)<lb/> AE with reasonable possibility of<lb/> being drug-related a<lb/> 122 (35.5)<lb/> 153 (44.0)<lb/> Severe AE<lb/> 14 (4.1)<lb/> 25 (7.2)<lb/> SAE<lb/> 4 (1.2)<lb/> 10 (2.9)<lb/> SAE with reasonable possibility<lb/> of being drug related a<lb/> 2 (0.6)<lb/> 4 (1.1)<lb/> AE leading to discontinuation of<lb/> study drug<lb/> 4 (1.2)<lb/> 7 (2.0)<lb/> AE leading to death b<lb/> 0<lb/> 1 (0.3)<lb/> AEs of special interest<lb/> Serious infections<lb/> 2 (0.6)<lb/> 4 (1.1)<lb/> Opportunistic infection,<lb/> excluding tuberculosis and<lb/> herpes zoster c<lb/> 0<lb/> 1 (0.3)<lb/> Herpes zoster<lb/> 3 (0.9)<lb/> 7 (2.0)<lb/> Active tuberculosis<lb/> 0<lb/> 0<lb/> Nonmelanoma skin cancer d<lb/> 1 (0.3)<lb/> 0<lb/> Malignant neoplasm, excluding<lb/> NMSC<lb/> 0<lb/> 0<lb/> Lymphoma<lb/> 0<lb/> 0<lb/> Hepatic disorder e<lb/> 4 (1.2)<lb/> 10 (2.9)<lb/> Adjudicated gastrointestinal<lb/> perforations<lb/> 0<lb/> 0<lb/> Anemia<lb/> 1 (0.3)<lb/> 7 (2.0)<lb/> Neutropenia<lb/> 2 (0.6)<lb/> 6 (1.7)<lb/> Lymphopenia<lb/> 0<lb/> 2 (0.6)<lb/> Creatine phosphokinase<lb/> elevation<lb/> 10 (2.9)<lb/> 23 (6.6)<lb/> Renal dysfunction<lb/> 1 (0.3)<lb/> 1 (0.3)<lb/> Adjudicated major adverse<lb/> cardiovascular events<lb/> 0<lb/> 0<lb/> Adjudicated venous<lb/> thromboembolic events<lb/> 0<lb/> 0<lb/> TEAEs reported by ≥5% in either<lb/> treatment group<lb/> Acne f<lb/> 9 (2.6)<lb/> 55 (15.8)<lb/> Dermatitis atopic<lb/> 29 (8.4)<lb/> 24 (6.9)<lb/> Upper respiratory tract infection 13 (3.8)<lb/> 22 (6.3)<lb/> Blood CPK level increased<lb/> 10 (2.9)<lb/> 23 (6.6)<lb/> Nasopharyngitis<lb/> 22 (6.4)<lb/> 20 (5.7)<lb/> Headache<lb/> 21 (6.1)<lb/> 14 (4.0)<lb/> Conjunctivitis<lb/> 29 (8.4)<lb/> 5 (1.4)<lb/> Abbreviations: AE, adverse event; CPK, creatine phosphokinase;<lb/> NMSC, nonmelanoma skin cancer; SAE, serious AE; TB, tuberculosis;<lb/> TEAE, treatment-emergent adverse event.<lb/> </table>
<lb/> 
            <note>a As assessed by investigator.</note>
		</figure>



    </text>
</tei>

